1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Idiopathic Short Stature - Pipeline Review, H1 2015

Idiopathic Short Stature - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 36 pages

Idiopathic Short Stature - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Idiopathic Short Stature - Pipeline Review, H1 2015’, provides an overview of the Idiopathic Short Stature’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Short Stature, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Short Stature and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Short Stature
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic Short Stature and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic Short Stature products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic Short Stature pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Short Stature
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic Short Stature pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Idiopathic Short Stature - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic Short Stature Overview 6
Therapeutics Development 7
Pipeline Products for Idiopathic Short Stature - Overview 7
Pipeline Products for Idiopathic Short Stature - Comparative Analysis 8
Idiopathic Short Stature - Therapeutics under Development by Companies 9
Idiopathic Short Stature - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Idiopathic Short Stature - Products under Development by Companies 13
Idiopathic Short Stature - Companies Involved in Therapeutics Development 14
Bolder Biotechnology, Inc. 14
Braasch Biotech LLC 15
Dong-A Socio Group 16
LG Life Sciences, Ltd. 17
Myungmoon pharmaceutical Co.,Ltd. 18
Idiopathic Short Stature - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 24
Drug Profiles 26
BBT-031 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
MM-P02-01 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
somatropin - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
somatropin SR - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Vaccine for Growth Hormone Deficiencies - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Idiopathic Short Stature - Recent Pipeline Updates 32
Idiopathic Short Stature - Dormant Projects 33
Idiopathic Short Stature - Discontinued Products 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables

Number of Products under Development for Idiopathic Short Stature, H1 2015 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Idiopathic Short Stature - Pipeline by Bolder Biotechnology, Inc., H1 2015 14
Idiopathic Short Stature - Pipeline by Braasch Biotech LLC, H1 2015 15
Idiopathic Short Stature - Pipeline by Dong-A Socio Group, H1 2015 16
Idiopathic Short Stature - Pipeline by LG Life Sciences, Ltd., H1 2015 17
Idiopathic Short Stature - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 22
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Idiopathic Short Stature Therapeutics - Recent Pipeline Updates, H1 2015 32
Idiopathic Short Stature - Dormant Projects, H1 2015 33
Idiopathic Short Stature - Discontinued Products, H1 2015 34

List of Figures

Number of Products under Development for Idiopathic Short Stature, H1 2015 7
Number of Products under Development for Idiopathic Short Stature - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Veterinary vaccines are extensively used in the prevention of life-threatening animal diseases. This report on the global veterinary vaccines market analyzes the current and future prospects of the market. ...

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Human Vaccines Market: Scope and Methodology This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human ...

Global Veterinary Vaccines Market

October 2016 $ 4250

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.